Navigation Links
Ethicon Endo-Surgery Submits Application to FDA for Approval of the SEDASYS(TM) System - the First Computer-Assisted Personalized Sedation System
Date:3/27/2008

CINCINNATI, March 27 /PRNewswire/ -- Ethicon Endo-Surgery announced today that the company has submitted a Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the SEDASYS(TM) System, the first computer-assisted personalized sedation (CAPS) system.

The SEDASYS(TM) System is intended for use by physician/nurse teams to administer minimal to moderate propofol sedation to patients undergoing screening and diagnostic procedures for colorectal cancer (colonoscopy), and disorders of the upper gastrointestinal tract (EGD). For routine colonoscopy or EDG procedures, physicians prefer the sedative propofol (also known as DIPRIVAN(R)), which produces rapid onset and quick recovery for patients(i).

The PMA submission includes results from a multi-center prospective, randomized, controlled trial of 1,000 patients that compared the safety and effectiveness of the SEDASYS(TM) System to the current standard of care for sedation in routine endoscopic procedures - physician-administered benzodiazepine and opioids. The pivotal clinical trial was conducted from March 2007 to October 2007 at eight locations in the U.S.

About Ethicon Endo-Surgery

Ethicon Endo-Surgery, a Johnson & Johnson company, develops and markets advanced medical devices for minimally invasive and open surgical procedures, focusing on procedure-enabling devices for the interventional diagnosis and treatment of conditions in general and bariatric surgery, as well as gastrointestinal health, gynecology and surgical oncology. More information can be found at http://www.ethiconendo.com.

SEDASYS is a trademark of Ethicon Endo-Surgery

DIPRIVAN(R) is a registered trademark of the AstraZeneca group of companies.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expecta
'/>"/>

SOURCE Ethicon Endo-Surgery
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
2. Global Med Technologies(R), Inc. Submits ElDorado Donor(TM) to FDA
3. Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate
4. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
5. ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily)
6. Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
7. ImaRx Therapeutics Submits Urokinase Data to FDA Supporting Extended Expiration Dating
8. XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe
9. Takeda submits new drug application for alogliptin (syr-322) in the US
10. Phyhealth Submits HMO Applications with Required Federal and State Agencies
11. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 03, 2015 Celestix Networks, the ... today announced the global availability of Celestix Cloud ... the world’s most deployed platform for DirectAccess and ... R2. This new release enables organizations to manage ... from a single HTML 5 web interface called ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Jack Coats, ... that Mr. William A. Breukelman has been named to ... completed development of the first fully integrated version of ... capable of analyzing the three-dimensional motion of the heart ... comparing the analysis at 15,300 points to the motion ...
(Date:3/3/2015)... 03, 2015 Using an “intelligent,” rather ... Medicare Part D prescription drug coverage plans could save ... new University of Pittsburgh Graduate School of Public Health ... the March issue of the journal Health Affairs and ... have saved more than $5 billion in its Part ...
(Date:3/3/2015)... Miami, FL (PRWEB) March 03, 2015 ... to be an international keynote presenter at the ... at the Melbourne Convention and Exhibition Centre March ... on Wednesday, March 11, at 11 am (Melbourne ... Emotions and Interests,” will discuss making each customer’s ...
(Date:3/3/2015)... A recent study of the correlation ... and radio host Sharon Kleyne has been saying for ... water in the body – is extremely widespread ... the US population. Kleyne further believes that research will ... all disease, including aging and stroke. , ...
Breaking Medicine News(10 mins):Health News:Introducing Celestix Cloud Edge Security 2.0 for Increased Security in DirectAccess Client Management 2Health News:Introducing Celestix Cloud Edge Security 2.0 for Increased Security in DirectAccess Client Management 3Health News:William A. (Bill) Breukelman Named to CardioWise, Inc. Board of Directors 2Health News:William A. (Bill) Breukelman Named to CardioWise, Inc. Board of Directors 3Health News:Medicare and Patients with Schizophrenia Could Save $150 Million on Part D Plans 2Health News:Medicare and Patients with Schizophrenia Could Save $150 Million on Part D Plans 3Health News:South Florida-based PureFormulas will discuss personalization at ecommerce Conference and Expo in Melbourne, Australia 2Health News:Study linking dehydration and stroke severity supports fresh water advocate’s warnings 2Health News:Study linking dehydration and stroke severity supports fresh water advocate’s warnings 3
... HealthDay Reporter , THURSDAY, Aug. 25 (HealthDay News) -- For kids, ... late and sleeping until noon: It also signals the beginning of ... Whether your child is a preschooler or a teen, some ... for parents is to know how to ease your children,s stress ...
... HealthDay Reporter , THURSDAY, Aug. 25 (HealthDay News) -- An ... finds that children,s vaccines are typically safe, with bad reactions ... problems. The IOM committee also agreed that there is ... later onset of conditions such as autism or type 1 ...
... the basis of new and effective treatments for ovarian ... and Portsmouth. The scientists are developing ... to stop cells from ovarian tumours growing. In initial ... from cancer patients. The extracts are complex mixtures ...
... 2011 -- Heart rate and blood pressure regulation may hold ... a new study by researchers at Wake Forest Baptist Medical ... as orthostatic intolerance (OI), which causes dizziness and occasional fainting ... debilitating chronic nausea in patients., "There seems to be a ...
... diagnostic imaging technique, physicians now have an objective test ... disease. Northwestern Memorial Hospital is among the first institutions ... imaging agent for assessment of movement disorders. Until now, ... forcing physicians to rely on clinical examinations to make ...
... An analysis of more than 1,000 research articles ... clearly associated with vaccines. A committee of experts ... scientific literature on possible adverse effects of vaccines found ... inflammation of the brain, and fainting -- that can ...
Cached Medicine News:Health News:Parents Can Ease Back-to-School Stress 2Health News:Parents Can Ease Back-to-School Stress 3Health News:U.S.-Mandated Report Finds Vaccines Safe for Kids 2Health News:U.S.-Mandated Report Finds Vaccines Safe for Kids 3Health News:U.S.-Mandated Report Finds Vaccines Safe for Kids 4Health News:Plants could pave the way for new ovarian cancer treatments 2Health News:Heart may hold key to unexplained nausea in youths 2Health News:New imaging test gives physicians better tool to diagnose Parkinson's disease 2Health News:New imaging test gives physicians better tool to diagnose Parkinson's disease 3Health News:Few health problems are caused by vaccines, IOM report finds 2Health News:Few health problems are caused by vaccines, IOM report finds 3
(Date:3/3/2015)... , March 3, 2015  HeartIT is ... the first Cardiac Magnetic Resonance Solution in the ... within a standard web browser. Precession™ combines zero ... features unmatched in the industry. This provides CMR ... all the critical functions of a successful CMR ...
(Date:3/3/2015)... NEWARK, Calif. , March 3, 2015 Depomed, ... will be presenting at the 27 th Annual Roth ... presentation is scheduled for 12:30 pm ET (9:30 am PT) ... webcast, and the webcast can be accessed via the Investor ... A recording of the webcast will be archived for 30 ...
(Date:3/3/2015)... March 3, 2015  MabVax Therapeutics (OTCQB: MBVX), a cancer ... , the Company,s President and CEO, will be presenting at ... March 9 – 12, 2015 at the Ritz Carlton in ... MabVax,s presentation is scheduled for Wednesday, March 11 th , ... for review on the Investor Relations section of the Company,s ...
Breaking Medicine Technology:Precession Advances Medical Imaging by Delivering a Complete Cardiac Magnetic Resonance Platform in a Web Browser 2Depomed To Present At 27th Annual Roth Conference 2
... 25 BiPar Sciences, Inc., a,privately held biopharmaceutical ... has hired industry veterans Eric D. Malek as ... as vice president,for regulatory affairs. "Over the ... role in clinical,stage product partnerships involving major pharmaceutical ...
... ARBOR, Mich. Sept. 24 Velcura Therapeutics, Inc., ... with the,U.S. Food and Drug Administration (FDA) Sept. ... of VEL-0230, a drug developed to treat bone,disease. ... (IND),meeting was to obtain feedback from the FDA,s ...
Cached Medicine Technology:BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer 2Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease 2Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease 3
... glucuronide (3alpha-diol G) is the glucuronide ... of dihydrotestosterone (DHT) [1,2]. 3alpha-diol G ... 75% of the bioactivity of testosterone ... product of intracellular reduction of DHT, ...
... Activins are polypeptide hormones which ... (TGF-) superfamily. The TGF- superfamily is ... factors which control many aspects of ... (1). Other members incude TGF-s, bone ...
... Gla protein, is a vitamin K-dependent, calcium ... of the noncollagenous bone matrix [1,2,3]. Osteocalcin ... a small amount produced by odontoblasts in ... formation, newly synthesized osteocalcin is incorporated into ...
... binding protein-2 (IGFBP-2) is one of six ... which specifically bind and modulate the actions ... of IGFBP-2 for IGF-II is estimated to ... suggesting a role in regulation of IGF-II ...
Medicine Products: